Summary

Eligibility
for females ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
completion around

Description

Summary

The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC).

The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).

Official Title

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Keywords

Endometrial Cancer, Endometrial Neoplasms, Paclitaxel, Doxorubicin, Sacituzumab govitecan, Sacituzumab govitecan-hziy, Sacituzumab Govitecan (SG)

Eligibility

Locations

  • UC San Diego Medical Center accepting new patients
    La Jolla California 92093 United States
  • City of Hope accepting new patients
    Duarte California 91010 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Gilead Sciences
Links
Gilead Clinical Trials Website
ID
NCT06486441
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 520 study participants
Last Updated